Answers are grounded in this paper and cite their sources.
Demonstrates that Lacticaseibacillus rhamnosus C51 reduces colitis severity in high proteolytic IBD microbiota colonized mice, suggesting a potential therapeutic pathway.
Background Microbial proteolytic imbalance occurs in about 30% of patients with inflammatory bowel disease (IBD), yet drivers and therapies targeting this dysfunction remain unknown. A high salt diet (HSD) is associated with increased colitis risk and higher predicted microbial proteases. Whether HSD-induced high proteolytic activity (PA) increases colitis risk or responds to anti-proteolytic therapy remains unknown. Aims 1. To determine whether HSD-induced high PA (HPA) microbiota worsens colitis severity. 2. To test whether elafin-producing Lacticaseibacillus rhamnosus (LrC51) prevents spontaneous colitis in mice colonized with HPA-IBD microbiota. Methods Adult germ-free (GF) C57BL/6 mice were colonized with low PA-IBD microbiota that induced a switch to HPA after HSD (HSD “responder”) or IBD microbiota that did not respond to HSD (“non-responder”). Mice were fed either a control diet (CD) or an isocaloric HSD supplemented with 4% NaCl (HSD). After three weeks, all mice were fed a CD and subjected to 1.5% dextran sodium sulfate (DSS) for 5 days followed by 2 days of water. Fecal blood was evaluated daily during colitis. Adult GF Il10-/- mice were colonized with HPA-IBD microbiota and fed a CD. After 3 weeks, mice received daily oral gavages with LrC51, wild-type (WT) control (Lcr35), or PBS+15% glycerol for 2 weeks. Cecal PA was measured (azocasein & FITC-elastin assays), and terminal ileum and colon was collected for histological analysis. Results In mice colonized with responder IBD microbiota, a HSD led to more severe fecal blood on average versus both HSD-responder and non-responder colonized mice fed a CD (p = 0.08 and p = 0.02, respectively). In Il10-/- mice colonized with HPA-IBD microbiota, LrC51 reduced microscopic scores in the colon and ileum compared with both WT (p < 0.001) and vehicle control (p < 0.01). LrC51 treated mice had lower overall proteolytic activity in the cecum (p = 0.04) compared to WT controls. Conclusions Mice colonized with HSD-responder microbiota and fed a HSD prior to low-grade DSS develop severe clinical signs of colitis. In the spontaneous Il10-/- model, the anti-protease producing probiotic LrC51, ameliorated colitis in HPA-IBD microbiota colonized mice. This probiotic is biocontained and its WT form is commercially available, which could rapidly translate to application in humans with IBD.
No takes yet. Share an insight, caveat, or question.
Bowerman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: